compounded semaglutide fda ruling The market for GLP-1 drugs remained robust despite the end of (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) shortages, with many facilities adding ingredients like B vitamins and some operating with FDA free to pursue semaglutide

10.1097/MED.0b013e32834190b5 19 HalimM

Identification of new indications for FDA-approved medications can occur in a serendipitous fashion in which a drug shows unexpected benefits in clinical trials for its original indication

Multiple randomized controlled trials and meta-analyses in patients with type 2 diabetes and obesity demonstrate that GLP-1RA therapy either preserves or modestly increases bone mineral density (BMD) at key skeletal sites lumbar spine and hip, GLP-1RAs also favorably modulate bone turnover markers, increasing bone formation markers (P1NP, osteocalcin, bone-specific alkaline phosphatase) and reducing bone resorption markers (-CTX), suggesting a net positive or neutral effect on bone remodeling

Specialized testing for tirzepatide levels is not performed in routine clinical practice

They are commonly referred to as phase II enzymes

Common gastrointestinal effects may occur, particularly during the first 12 weeks as the gut microbiome adjusts